Open AccessS857 Patient-Reported Outcomes of Response and Remission Following Guselkumab Induction Treatment as Measured by the Inflammatory Bowel Disease Questionnaire: Results Through Week 12 of the Phase 2 GALAXI 1 Study
Author(s) -
David T. Rubin,
Remo Panaccione,
Geert R. D’Haens,
Chenglong Han,
Susana Gonzalez,
Kathleen Weisel,
Mary Ellen Frustaci,
Zijiang Yang,
Jewel Johanns,
Matthew Germinaro,
Silvio Danese,
Bruce E. Sands,
Julián Panés
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000776960.58058.bf
Subject(s) - medicine , inflammatory bowel disease , placebo , crohn's disease , population , vedolizumab , clinical endpoint , randomized controlled trial , quality of life (healthcare) , randomization , gastroenterology , physical therapy , disease , alternative medicine , environmental health , nursing , pathology